



DISCOVER DUPIXENT

A new biologic option in OCS-dependent or type 2 /
eosinophilic severe asthma*

Dear Doctor,

Sanofi Genzyme is pleased to announce that DUPIXENT (dupilumab injection) is now indicated as follows:

As an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma.

DUPIXENT is not indicated for relief of acute bronchospasm or status asthmaticus.

Consult the Product Monograph at <http://products.sanofi.ca/en/dupixent-en.pdf> for important information about:

- Relevant warnings and precautions regarding reduction of corticosteroid dosage, systemic hypersensitivity reactions, elevation of blood eosinophils, eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis, not studied with live vaccines, conjunctivitis and keratitis, patients with helminth infection, patients with concomitant atopic conditions, acute asthma symptoms or exacerbations, pregnant and nursing women, pediatric and geriatric patients
- Conditions of clinical use, adverse reactions, drug interactions and dosing/administration instructions

The Product Monograph is also available by calling us at 1-800-589-6215.

As always, we are here to answer any questions.

Regards,

The DUPIXENT Brand Team

OCS: oral corticosteroid

* Comparative clinical significance unknown.